Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Pfizer
Angela Hwang
At Pfizer, the pandemic has supercharged our mindset, our resilience, and our determination to address the health challenges we see around the world, including and beyond COVID-19. Thanks to the combination of our expertise and culture, we are conditioned to pursue excellence and never settle for good enough.
Angela Hwang is a member of Pfizer’s Executive Team and Group President of the Pfizer Biopharmaceuticals Group, which is the commercial organization of Pfizer. Her organization of 26,000 colleagues across 125 countries is responsible for bringing over 600 innovative medicines and products to patients. In 2020, more than 420 million people benefited from a Pfizer Biopharma medicine or vaccine to improve their health and, in some cases, save their lives. Altogether, Pfizer Biopharma generated almost $42 billion in 2020 revenues.
As Group President of Pfizer Biopharma, Angela leads 7 commercial business units. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.
Angela is a member of the Board of Directors of UPS, EFPIA (European Federation of Pharmaceutical Industries and Associations), as well as the Pfizer Foundation, a charitable organization that addresses global health challenges. In 2019, she was named in Crain’s Notable Women in Healthcare list. In 2021, she was ranked #11 in Fortune’s Top 50 Most Powerful Women list, and recognized in Forbes’ inaugural CEO Next list. She has also been honored as one of Modern Healthcare’s Top 25 Women Leaders, and as an A100 Honoree, which celebrates the 100 most impactful AAPI leaders of the past year. She received the President’s AwardTM from the National Diversity Council in 2021, for her efforts to champion diversity, equity, and inclusion.
Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and her MBA from Cornell University, where she remains a Member of the Advisory Council of the SC Johnson Graduate School of Business. She is a wife and proud mom to a teenage son and daughter, and a strong advocate for women’s leadership and sustainable global health equity.
As Group President of Pfizer Biopharma, Angela leads 7 commercial business units. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.
Angela is a member of the Board of Directors of UPS, EFPIA (European Federation of Pharmaceutical Industries and Associations), as well as the Pfizer Foundation, a charitable organization that addresses global health challenges. In 2019, she was named in Crain’s Notable Women in Healthcare list. In 2021, she was ranked #11 in Fortune’s Top 50 Most Powerful Women list, and recognized in Forbes’ inaugural CEO Next list. She has also been honored as one of Modern Healthcare’s Top 25 Women Leaders, and as an A100 Honoree, which celebrates the 100 most impactful AAPI leaders of the past year. She received the President’s AwardTM from the National Diversity Council in 2021, for her efforts to champion diversity, equity, and inclusion.
Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and her MBA from Cornell University, where she remains a Member of the Advisory Council of the SC Johnson Graduate School of Business. She is a wife and proud mom to a teenage son and daughter, and a strong advocate for women’s leadership and sustainable global health equity.
